Plexium

SAN DIEGO, CA · CIK 0002082715 · Biotech · Private

Targeted protein degradation molecules using monovalent direct degraders and molecular glues

plexium.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$60M
1 Form D · Aug 2025
13 months since last filing
Contracts
—
No federal contracts on record
Patents
40
17 granted · 23 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$60,115,703
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2452PALM THERAPEUTICS, INC.——
2453ILLUMINATE THERAPEUTICS, INC.——
2454TERAPORE TECHNOLOGIES, INC.—$3.5M
2455Plexium—$60M
2456Prolific Machines—$55M
2457LIFESPLICE PHARMA, LLC——
2458ImmusanT, Inc.—$33M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Leon ChenDirector
  • Cariad ChesterDirector
  • Michael GreyDirector
  • Rob HopfnerDirector
  • Gorjan HrustanovicDirector
  • Michael MartinDirector · Executive Officer
  • Serge MesserlianDirector
  • Stephen MullennixExecutive Officer
  • Patrick RiversDirector

Patents

USPTO · 17 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.